![In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT](https://www.statnews.com/wp-content/uploads/2024/05/AdobeStock_351116154-645x645.jpeg)
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.
But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.
The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.
![STAT+](https://www.statnews.com/wp-content/uploads/2022/02/stat_plus_hero_new-2048x502.png)
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect